Recent 8-K filings for DXR

• June 24, 2026, 4:10 PM ET other material materiality 0.15 neutral item 5.07

  Daxor shareholders elect all six director nominees and ratify auditor at annual meeting

  All six director nominees elected for terms expiring in 2027.

• January 26, 2026, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements ×2

  Daxor raises ~$8.1M in registered direct offering of 765,958 shares at $11.75/share

  Sold 765,958 shares at $11.75 per share for net proceeds of approx. $8,142,006 after fees.

• January 23, 2026, 6:59 PM ET other materiality 0.10 neutral item 8.01item 9.01

  Daxor files 8-K with investor presentation; no details available from provided text

  Daxor Corporation issued a regulatory filing attaching an investor presentation on January 23, 2026.

• August 7, 2025, 7:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  Daxor receives FDA 510(k) clearance for next-gen blood volume analyzer

  FDA 510(k) clearance (K251087) for patent-pending rapid, hand-held BVA device.

• July 1, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Daxor reports annual meeting voting results; all director nominees elected, auditor ratified

  All six director nominees elected; votes for ranged from 3,473,576 to 3,493,651.

• July 18, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

  Daxor holds annual meeting; re-elects six directors, ratifies auditor

  All six director nominees elected with over 3.5M votes for each; no new directors.

• June 5, 2024, 7:59 PM ET regulatory materiality 0.25 neutral item 3.01

  Daxor resolves Nasdaq audit committee deficiency with appointment of Caleb DesRosiers

  Nasdaq notified Daxor on May 30, 2024 of non-compliance with audit committee rule due to death of James A. Lombard.

• March 25, 2024, 7:59 PM ET M&A materiality 0.75 positive item 8.01item 9.01

  Daxor acquires worldwide rights to Volumex, Megatope, and Glofil from Iso-Tex Diagnostics

  No upfront payment; seller-financed with monthly installments starting after manufacturing transition in 6–9 months.

• January 2, 2024, 6:59 PM ET regulatory materiality 0.65 neutral item 8.01item 9.01

  Daxor submits next-gen BVA to FDA for 510(k)/CLIA-waiver; clearance expected H1 2024

  Submission via dual 510(k)/CLIA-waiver pathway to FDA for next-generation blood volume analyzer.

• November 28, 2023, 6:59 PM ET other material materiality 0.40 neutral item 8.01

  Daxor allocates $550K of May 2023 offering proceeds to hematocrit capability development

  Net proceeds of $3.56M from May 22, 2023 public offering of 410,260 shares at $9.75/share.

• October 27, 2023, 7:59 PM ET other material materiality 0.45 neutral item 8.01

  Daxor allocates $1.9M of May 2023 offering proceeds to optical blood volume analyzer development

  Net proceeds of $3,555,532 from 410,260 shares at $9.75/share in May 2023 public offering.

• July 13, 2023, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Daxor shareholders elect seven directors, ratify auditor at annual meeting

  Elected James Lombard, Henry Cremisi, Edward Feuer, Joy Goudie, Michael Feldschuh, Jonathan Feldschuh, Caleb DesRosiers as directors.

• May 26, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Daxor closes $4.0M public offering of 410,260 shares at $9.75/share

  Closed underwritten public offering of 410,260 shares at $9.75 per share, raising $4.0M gross.

• November 21, 2022, 6:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  Daxor closes $2.1M underwritten public offering of 221,050 shares at $9.50/sh

  Closed offering of 210,527 shares plus partial overallotment of 10,523 shares, total 221,050 shares.

• June 29, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

  Daxor annual meeting elects directors, approves compensation plan and written consent amendments

  All seven director nominees elected with majority votes; broker non-votes ranged from 504,940 to 540,940.

• February 2, 2022, 6:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  Daxor begins trading on Nasdaq Capital Markets, will ring Opening Bell on Feb 4, 2022

  Daxor commenced trading on Nasdaq Capital Markets effective Feb 2, 2022, moving from NYSE American (ticker DXR).

• January 24, 2022, 6:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

  Daxor appoints Caleb DesRosiers to Board of Directors

  Caleb DesRosiers, JD, MPA, appointed to Board effective January 18, 2022, until next annual meeting.

• January 20, 2022, 6:59 PM ET other material materiality 0.50 neutral item 3.01item 9.01

  Daxor to transfer stock listing to Nasdaq Capital Market on Feb 2, 2022

  Effective Feb 2, 2022, Daxor's common stock will trade on Nasdaq Capital Market under ticker DXR.

Executive changes

Materiality & sentiment trend

Max materiality 0.75 · Median 0.43 · Most common event other_material

3 positive 0 negative 15 neutral

source · DXR on sec.gov